Allurion Technologies (ALUR) Stock Price, News & Analysis

Company Overview

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

Key Stats

• Today's Range: $0.61 to $0.65
• 50-Day Range: $0.57 to $0.89
• 52-Week Range: $0.55 to $5.15
• Volume: 38,213 shs
• Average Volume: 828,580 shs
• Market Capitalization: $30.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.17
• Consensus Rating: Buy

Allurion Technologies Stock Analysis - MarketRank™

Allurion Technologies scored higher than 39% of companies evaluated by MarketBeat, and ranked 773rd out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Allurion Technologies has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Allurion Technologies has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Allurion Technologies are expected to decrease in the coming year, from ($0.30) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Allurion Technologies is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Allurion Technologies is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.40% of the float of Allurion Technologies has been sold short.

Short Interest Ratio / Days to Cover

Allurion Technologies has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allurion Technologies has recently increased by 16.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allurion Technologies does not currently pay a dividend.

Dividend Growth

Allurion Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.40% of the float of Allurion Technologies has been sold short.

Short Interest Ratio / Days to Cover

Allurion Technologies has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Allurion Technologies has recently increased by 16.63%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Allurion Technologies has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Allurion Technologies this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ALUR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Allurion Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Allurion Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.00% of the stock of Allurion Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 21.39% of the stock of Allurion Technologies is held by institutions.

ALUR Stock Analysis - Frequently Asked Questions

How have ALUR shares performed this year?

Allurion Technologies' stock was trading at $3.74 at the start of the year. Since then, ALUR stock has decreased by 83.3% and is now trading at $0.6256.
View the best growth stocks for 2024 here.

How were Allurion Technologies' earnings last quarter?

Allurion Technologies Inc. (NYSE:ALUR) issued its earnings results on Tuesday, August, 13th. The company reported $0.01 EPS for the quarter. The firm had revenue of $11.77 million for the quarter.

How do I buy shares of Allurion Technologies?

Shares of ALUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/13/2024
• Today: 9/28/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ALUR
• Previous Symbol: NYSE:ALUR
• CUSIP: N/A
• CIK: 1964979
• Web: www.allurion.com
• Phone: 508-647-4000
• Fax: N/A
• Employees: 501
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.17
• High Stock Price Target: $5.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +406.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-80,610,000.00
• Net Margins: -78.56%
• Pretax Margin: -77.83%
• Return on Equity: N/A
• Return on Assets: -64.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.71
• Quick Ratio: 1.51

Sales & Book Value

• Annual Sales: $47.59 million
• Price / Sales: 0.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.48) per share
• Price / Book: -0.42

Miscellaneous

• Outstanding Shares: 47,948,000
• Free Float: 38,358,000
• Market Cap: $30.00 million
• Optionable: Optionable
• Beta: -0.33